Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01831089 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
A Phase 1 study, sponsored by PharmaMar.
- Completed
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
NCT01831089 is a Phase 1 study that has completed, run by PharmaMar. The registered enrollment target is 69 participants.
The verdict
NCT01831089, a Phase 1 study, has completed, sponsored by PharmaMar.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
Study Summary
Clinical trial of PM01183 in combination with paclitaxel, with or without bevacizumab, in patients with solid tumors
Interventions
- DRUG PM01183 + paclitaxel +/- bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2013-09 |
| Est. Completion | 2016-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01831089
The ClinicalTrials.gov registry entry for NCT01831089 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PharmaMar, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PM01183 + paclitaxel +/- bevacizumab is the first listed.
NCT01831089 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01831089 about?
NCT01831089 is a clinical study titled "Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors". Clinical trial of PM01183 in combination with paclitaxel, with or without bevacizumab, in patients with solid tumors
What is the current status of trial NCT01831089?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2013-09. Estimated completion is 2016-07.
What interventions are being tested in trial NCT01831089?
The interventions under investigation include: PM01183 + paclitaxel +/- bevacizumab (DRUG).
Who is sponsoring clinical trial NCT01831089?
This trial is sponsored by PharmaMar, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.